Typ-1-Diabetes bei Kindern früh erkennen und präventiv handeln

ZUSAMMENFASSUNG

Typ-1-Diabetes ist die häufigste chronische Stoffwechselerkrankung im Kindes- und Jugendalter, mit steigenden Inzidenzraten. Die Autoimmunerkrankung kann heute bereits in einem frühen Stadium – noch bevor Symptome auftreten – durch Antikörpertests sicher diagnostiziert werden. Die Fr1da-Studie verfolgt das Ziel, Typ-1-Diabetes bei Kindern im präsymptomatischen Frühstadium zu erkennen, durch Schulung und Monitoring schwere Stoffwechselentgleisungen bei Betroffenen zu verhindern und ihnen die Teilnahme an klinischen Studien mit neuen, potenziell präventiven Therapien zu ermöglichen. Die Durchführbarkeit und der Nutzen eines bevölkerungsweiten Screenings für Typ-1-Diabetes bei Kindern sollen evaluiert werden. Die Aufnahme der Früherkennungsuntersuchung in die medizinische Regelversorgung wird angestrebt.

Publication History

Article published online:
17 May 2022

• Literatur

• 1 Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014; 383: 69-82
• 2 IDF Diabetes Atlas. 9th. International Diabetes Federation (IDF); 2019 20.04.2020
• 3 Patterson CC, Karuranga S, Salpea P. et al Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Research and Clinical Practice 2019; 157: 107842
• 4 Harjutsalo V, Sjöberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008; 371: 1777-1782
• 5 Ziegler AG, Bonifacio E. BABYDIAB-BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 2012; 55: 1937-1943
• 6 Parikka V, Näntö-Salonen K, Saarinen M. et al Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012; 55: 1926-1936
• 7 Krischer JP, Lynch KF, Schatz DA. et al The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 2015; 58: 980-987
• 8 Bonifacio E, Achenbach P. Birth and coming of age of islet autoantibodies. Clin Exp Immunol 2019; 198: 294-305
• 9 Ziegler AG, Rewers M, Simell O. et al Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309: 2473-2479
• 10 Insel RA, Dunne JL, Atkinson MA. et al Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015; 38: 1964-1974
• 11 American Diabetes Association 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43: S14-S31
• 12 Rewers A, Dong F, Slover RH. et al Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998–2012. JAMA 2015; 313: 1570-1572
• 13 Karges B, Neu A, Hofer S. et al Frequency and influencing factors of ketoacidosis at diabetes onset in children and adolescents--a long-term study between 1995 and 2009. Klinische Pädiatrie 2011; 223: 70-73
• 14 Alonso GT, Coakley A, Pyle L. et al Diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado children, 2010–2017. Diabetes Care 2020; 43: 117-121
• 15 Eppens MC, Craig ME, Cusumano J. et al Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 2006; 29: 1300-1306
• 16 Livingstone SJ, Levin D, Looker HC. et al Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA 2015; 313: 37-44
• 17 Fredheim S, Johannesen J, Johansen A. et al Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA 1c levels. Diabetologia 2013; 56: 995-1003
• 18 Cameron FJ, Scratch SE, Nadebaum C. et al Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children. Diabetes Care 2014; 37: 1554-1562
• 19 Duca LM, Wang B, Rewers M. et al Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care 2017; 40: 1249-1255
• 20 Kovacs M, Finkelstein R, Feinberg TL. et al Initial Psychologic Responses of Parents to the Diagnosis of Insulin-dependent Diabetes Mellitus in Their Children. Diabetes Care 1985; 08: 568-575
• 21 Hauenstein EJ, Marvin RS, Snyder AL. et al Stress in Parents of Children With Diabetes Mellitus. Diabetes Care 1989; 12: 18-23
• 22 Viner R, McGrath M, Trudinger P. Family stress and metabolic control in diabetes. Arch Dis Child 1996; 74: 418-421
• 23 Larsson HE, Vehik K, Bell R. et al Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care 2011; 34: 2347-2352
• 24 Hekkala AM, Ilonen J, Toppari J. et al Ketoacidosis at diagnosis of type 1 diabetes: effect of prospective studies with newborn genetic screening and follow up of risk children. Pediatric Diabetes 2018; 19: 314-319
• 25 Herold KC, Bundy BN, Long SA. et al An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med 2019; 381: 603-613
• 26 Quattrin T, Haller MJ, Steck AK. et al Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. N Engl J Med 2020; 383: 2007-2017
• 27 Sims EK, Bundy BN, Stier K. et al Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 2021; 13: eabc8980
• 28 Raab J, Haupt F, Scholz M. et al Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open 2016; 06: e011144
• 29 Amoroso M, Achenbach P, Powell M. et al 3 Screen islet cell autoantibody ELISA: A sensitive and specific ELISA for the combined measurement of autoantibodies to GAD65, to IA-2 and to ZnT8. Clin Chim Acta 2016; 462: 60-64
• 30 Ziegler AG, Haupt F, Scholz M. et al 3 Screen ELISA for High-Throughput Detection of Beta Cell Autoantibodies in Capillary Blood. Diabetes Technol Ther 2016; 18: 687-693
• 31 Liberati D, Wyatt RC, Brigatti C. et al A novel LIPS assay for insulin autoantibodies. Acta Diabetol 2018; 55: 263-270
• 32 Ziegler AG, Kick K, Bonifacio E. et al Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany. JAMA 2020; 323: 339-351
• 33 Insel RA, Dunne JL, Ziegler AG. General population screening for type 1 diabetes: has its time come?. Curr Opin Endocrinol Diabetes Obes 2015; 22: 270-276
• 34 Hippich M, Holthaus L, Assfalg R. et al A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. Med (N Y) 2021; 02: 149-163.e4
• 35 Hippich M, Sifft P, Zapardiel-Gonzalo J. et al A public health antibody screening indicates a marked increase of SARS-CoV-2 exposure rate in children during the second wave. Med (N Y) 2021; 02: 571-572
• 36 Segerer H, Wurm M, Grimsmann JM. et al Diabetic Ketoacidosis at Manifestation of Type 1 Diabetes in Childhood and Adolescence-Incidence and Risk Factors. Dtsch Arztebl Int 2021; 118: 367-372
• 37 Kamrath C, Monkemoller K, Biester T. et al Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany. JAMA 2020; 324: 801-804
• 38 Kick K, Assfalg R, Aydin S. et al Recruiting young pre-symptomatic children for a clinical trial in type 1 diabetes: Insights from the Fr1da insulin intervention study. Contemporary clinical trials communications 2018; 11: 170-173
• 39 Kick K, Hoffmann V, Lange K. et al Feasibility and organization of a population-based screening for pre-symptomatic type 1 diabetes in children — evaluation of the Fr1da study. Journal of Public Health 2019; 27: 553-560
• 40 Karl FM, Winkler C, Ziegler AG. et al Costs of Public Health Screening of Children for Presymptomatic Type 1 Diabetes in Bavaria, Germany. Diabetes Care 2022; 45: 837-844